A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants

Recruiting

Phase 1

Phase 2

DB-2304A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants

Sponsor:

DualityBio Inc.

Code:

NCT06625671

Conditions

Systemic Lupus Erythematosus (SLE)

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Accepted

Interventions

DB-2304

Placebo

Prednisone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-25. This information was provided to ClinicalTrials.gov by DualityBio Inc. on 2025-12-18.